<?xml version="1.0" encoding="UTF-8"?>
<!--Generated by Squarespace Site Server v5.0.0 (http://www.squarespace.com/) on Tue, 06 Jan 2009 23:21:21 GMT--><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0"><channel><title>Drug Disposition &amp; Pharmacokinetics</title><link>http://brainscienceblogs.com/drug-disposition-pharmacokine/</link><description></description><copyright></copyright><language>en-US</language><generator>Squarespace Site Server v5.0.0 (http://www.squarespace.com/)</generator><item><title>Drug Disposition &amp; Pharmacokinetics</title><category>Drug Disposition &amp; Pharmacokinetics</category><dc:creator>Contacts</dc:creator><pubDate>Tue, 25 Mar 2008 21:31:45 +0000</pubDate><link>http://brainscienceblogs.com/drug-disposition-pharmacokine/2008/3/25/drug-disposition-pharmacokinetics.html</link><guid isPermaLink="false">140403:2122211:1714295</guid><description><![CDATA[<p><a href="http://www.medworksmedia.com/psychopharmbulletin/index.php" target="_blank">Switching from Other Agents to Extended-Release Carbamazepine in Acute Mania<br />By Rif S. El-Mallakh, MD, Terence A. Ketter, MD, Richard H. Weisler, MD, Robert Hirschfeld, MD, Andrew J. Cutler, MD, Thomas Gazda, MD, Paul Keck, Jr, MD, Alan C. Swann, MD, and Amir H. Kalali, MD</a></p><p><a target="_blank" href="http://www.medworksmedia.com/psychopharmbulletin/index_archives.php?id=22">The Effect of Food on the Absorption of Oral Ziprasidone<br />By Jeffrey J. Miceli, PhD, Paul Glue, MD, PhD, Jeffrey Alderman, PhD, and Keith Wilner, PhD </a><br /></p><p><a href="http://www.medworksmedia.com/psychopharmbulletin/index_archives.php?id=21" target="_blank">Long-Acting Injectable Risperidone in the Treatment of Schizophrenia in Special Patient Populations<br />By Eduard Parellada, MD, MSc, PhD</a></p><p><a target="_blank" href="http://www.medworksmedia.com/psychopharmbulletin/index_archives.php?id=20">Drug&ndash;Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients<br />Robert R. Conley, MD and Deanna L. Kelly, PharmD, BCPP </a></p><p><a href="http://www.medworksmedia.com/psychopharmbulletin/index_archives.php?id=18" target="_blank">Efficacy of Olanzapine and Risperidone in Schizophrenia:A Randomized Double-Blind Crossover Design<br />By Jose M. Canive, MD, Gregory A Miller, PhD, Jessica G. Irwin, BS, Sandra N. Moses, PhD, Robert J. Thoma, PhD, J. Christopher Edgar, PhD, <br />Andrea Sherwood, PhD, Fernando Torres, MD, Marianna LaNoue, PhD,&nbsp; Stephen Lewis, MD, Faith M. Hanlon, PhD, Michael P. Weisend, PhD, <br />Valerie Mead, MD, and Vicente B. Tuason, MD</a> </p><p>&nbsp;</p><a href="http://www.medworksmedia.com/psychopharmbulletin/index_archives.php?id=21" target="_blank"></a>
]]></description><wfw:commentRss>http://brainscienceblogs.com/drug-disposition-pharmacokine/rss-comments-entry-1714295.xml</wfw:commentRss></item></channel></rss>